Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual MeetingPRNewsWire • 06/13/26
Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.Investors Business Daily • 06/12/26
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry AboutThe Motley Fool • 06/12/26
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy24/7 Wall Street • 06/12/26
Pharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesZacks Investment Research • 06/11/26
I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow24/7 Wall Street • 06/10/26
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema CareZacks Investment Research • 06/10/26
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisPRNewsWire • 06/09/26
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive PlayInvestopedia • 06/09/26
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?Zacks Investment Research • 06/09/26